Insulin X10 Revisited: a Super-mitogenic Insulin Analogue

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2011 Jun 3

PMID 21633908

Citations 28

Authors

B F Hansen

P Kurtzhals

A B Jensen

A Dejgaard

D Russell-Jones

Affiliations

Soon will be listed here.

Abstract

The molecular safety of insulin analogues has received a great deal of attention over the last year. In particular, attention has been directed to the mitogenic properties of insulin analogues as compared with human insulin. Understanding the mechanisms implicated in mediating mitogenic effects of insulin is therefore of particular interest. In this review we detail the story of the rapid-acting insulin analogue known as X10, which was the first insulin analogue in clinical development, but ended up being discontinued at an early clinical development stage following findings of mammary tumours in female Sprague-Dawley rats. The molecular characteristics of insulin X10, along with its interaction at both the IGF-1 receptor and the insulin receptor, have provided us with important insights into mechanisms implicated in metabolic and mitogenic signalling of insulin analogues.

Citing Articles

The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.

Rosenstock J, Juneja R, Beals J, Moyers J, Ilag L, McCrimmon R Endocr Rev. 2024; 45(3):379-413.

PMID: 38224978 PMC: 11091825. DOI: 10.1210/endrev/bnad037.

Effects of Insulin on Proliferation, Apoptosis, and Ferroptosis in Primordial Germ Cells via PI3K-AKT-mTOR Signaling Pathway.

Ye L, Liu X, Jin K, Niu Y, Zuo Q, Song J Genes (Basel). 2023; 14(10).

PMID: 37895324 PMC: 10606282. DOI: 10.3390/genes14101975.

Insulin signaling and its application.

Le T, Dao X, Nguyen D, Luu D, Bui T, Le T Front Endocrinol (Lausanne). 2023; 14:1226655.

PMID: 37664840 PMC: 10469844. DOI: 10.3389/fendo.2023.1226655.

Minimizing Mitogenic Potency of Insulin Analogues Through Modification of a Disulfide Bond.

Ong S, Belgi A, Merriman A, Delaine C, van Lierop B, Andrikopoulos S Front Endocrinol (Lausanne). 2022; 13:907864.

PMID: 35832429 PMC: 9271792. DOI: 10.3389/fendo.2022.907864.

Survival Risk Analysis of Small Cell Lung Cancer Patients with Pre-Existing Type 2 Diabetes Mellitus: A Single-Center Retrospective Cohort Study.

Ding J, Li X, Ge J, Gong Y, Zhou Y, Xiao J Cancer Manag Res. 2022; 14:1313-1322.

PMID: 35386185 PMC: 8979423. DOI: 10.2147/CMAR.S340334.

References

Glendorf T, Knudsen L, Stidsen C, Hansen B, Hegelund A, Sorensen A . Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues. PLoS One. 2012; 7(2):e29198. PMC: 3285154. DOI: 10.1371/journal.pone.0029198. View

Tran T, Medline A, Bruce W . Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev. 1996; 5(12):1013-5. View

Schwartz G, Burke G, KATSOYANNIS P . A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci U S A. 1987; 84(18):6408-11. PMC: 299085. DOI: 10.1073/pnas.84.18.6408. View

Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A . Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002; 277(42):39684-95. DOI: 10.1074/jbc.M202766200. View

Renehan A, Tyson M, Egger M, Heller R, Zwahlen M . Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X. View

Ogunleye A, Ogston S, Morris A, Evans J . A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer. 2009; 101(7):1199-201. PMC: 2768085. DOI: 10.1038/sj.bjc.6605240. View

Bodmer M, Meier C, Krahenbuhl S, Jick S, Meier C . Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33(6):1304-8. PMC: 2875444. DOI: 10.2337/dc09-1791. View

Brange J, Ribel U, Hansen J, Dodson G, Hansen M, Havelund S . Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988; 333(6174):679-82. DOI: 10.1038/333679a0. View

Kang S, Creagh F, Peters J, Brange J, Volund A, Owens D . Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care. 1991; 14(7):571-7. DOI: 10.2337/diacare.14.7.571. View

10.

Oleksiewicz M, Bonnesen C, Hegelund A, Lundby A, Holm G, Jensen M . Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells. J Appl Toxicol. 2010; 31(4):329-41. DOI: 10.1002/jat.1590. View

11.

Hemkens L, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke G . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009; 52(9):1732-44. PMC: 2723679. DOI: 10.1007/s00125-009-1418-4. View

12.

Sommerfeld M, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R . In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One. 2010; 5(3):e9540. PMC: 2832019. DOI: 10.1371/journal.pone.0009540. View

13.

Berti L, Kellerer M, Capp E, Haring H . Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. Diabetologia. 1997; 40(5):606-9. DOI: 10.1007/s001250050722. View

14.

Jonasson J, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G . Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009; 52(9):1745-54. DOI: 10.1007/s00125-009-1444-2. View

15.

Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen A, Shaw A, Mathiasen I . Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem. 2006; 281(36):25869-74. DOI: 10.1074/jbc.M605189200. View

16.

Drejer K . The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev. 1992; 8(3):259-85. DOI: 10.1002/dmr.5610080305. View

17.

Slieker L, Brooke G, DiMarchi R, Flora D, Green L, Hoffmann J . Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia. 1997; 40 Suppl 2:S54-61. DOI: 10.1007/s001250051402. View

18.

Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D . Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer. 2009; 16(2):429-41. DOI: 10.1677/ERC-08-0240. View

19.

Coughlin S, Calle E, Teras L, Petrelli J, Thun M . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159(12):1160-7. DOI: 10.1093/aje/kwh161. View

20.

Kohn W, Micanovic R, Myers S, Vick A, Kahl S, Zhang L . pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides. 2007; 28(4):935-48. DOI: 10.1016/j.peptides.2007.01.012. View